ARA-290
Cibinetide — Innate Repair Receptor Agonist
Half-life: ~30 minutes (SC); effects on nerve fiber density persist weeks
Research Profile
Relative research assessments — educational reference only.
Target Receptors
Critical Research Warning
Research chemical — not for human consumption. Although well tolerated in Phase 2 trials, it is not an approved drug. Not for use in pregnancy.
"A non-erythropoietic peptide derived from erythropoietin (EPO) that activates the innate repair receptor. Studied in Phase 2 clinical trials for neuropathy, inflammation, and tissue protection without EPO’s red-cell effects."
Full Description
ARA-290 (cibinetide) is an 11-amino-acid peptide derived from the helix-B domain of erythropoietin (EPO). It selectively activates the innate repair receptor (a heterocomplex of EPO receptor and β-common receptor) while having no erythropoietic activity — meaning it does not stimulate red blood cell production. ARA-290 activates tissue-protective and anti-inflammatory signaling cascades, and has completed Phase 2 clinical trials for sarcoidosis-associated small fiber neuropathy, diabetic macular edema, and diabetic neuropathy, showing improvements in neuropathic symptoms and corneal nerve fiber density. It is also studied for islet transplantation and ischemic conditioning.
Mechanism of Action
Activates the innate repair receptor (EPOR/βcR heterodimer), triggering JAK2/STAT and PI3K/Akt anti-apoptotic and anti-inflammatory signaling in neurons, endothelial cells, and immune cells, without the JAK2-mediated erythropoiesis of EPO.
Reported Benefits
- • Reduced neuropathic pain in Phase 2 trials
- • Improved corneal nerve fiber density (nerve regeneration)
- • Anti-inflammatory without erythropoiesis
- • Protects islet grafts and ischemic tissue in models
Potential Side Effects
- • Injection site reactions
- • Headache
- • Mild gastrointestinal symptoms
- • Generally well tolerated in trials
Frequently Asked Questions
How is ARA-290 different from EPO?▼
What clinical evidence exists?▼
How is it dosed in trials?▼
For Research Reference Only
Not medical advice. Peptides may be regulated or restricted in your jurisdiction.
References
- 1.ARA 290 for treatment of small fiber neuropathy in sarcoidosis.. PubMed (2014). van Velzen M, et al.. pubmed.ncbi.nlm.nih.gov/24555851/ ↑
- 2.A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.. PubMed (2020). Lois N, et al.. pubmed.ncbi.nlm.nih.gov/32674280/ ↑
- 3.Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.. PubMed (2022). Al-Onaizi MA, et al.. pubmed.ncbi.nlm.nih.gov/34343617/ ↑
- 4.Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis.. PubMed (2017). Nairz M, et al.. pubmed.ncbi.nlm.nih.gov/29026145/ ↑
Where to Source ARA-290
0 vendors listed · ranked most → least trusted · not an endorsement
No vendors listed for ARA-290 yet.
Rankings are community-derived. Always independently verify COAs before any research use. PeptidePlaza is not affiliated with any vendor.
Sell ARA-290 on PeptidePlaza
Get listed as a verified vendor and reach researchers directly.